One such option that may be discussed based on our current observations in ACPA-negative RA patients is to test the selective cyclin-dependent kinase 4/6 (CDK4/6) inhibitor (Momilactone B) which is currently being investigated for treatment of colon cancer [51]. Here, PRTN3 is linked to colonic neoplasm.